BACKGROUND: Factor VIII (FVIII) and von Willebrand factor (VWF) circulate in plasma in a tight non-covalent complex, being critical to hemostasis. Although structurally unrelated, both share the presence of sialylated glycan-structures, making them potential ligands for sialic-acid-binding-immunoglobulin-like-lectins (Siglecs). DESIGN AND METHODS: We explored the potential interaction between FVIII/VWF and Siglec-5, a receptor expressed in macrophages using various experimental approaches, including binding experiments with purified proteins and cell-binding studies with Siglec-5 expressing cells. Finally, Siglec-5 was overexpressed in mice via hydrodynamic gene transfer. RESULTS: In different systems using purified proteins, saturable, dose-dependent and reversible interactions between a soluble Siglec-5 fragment and both hemostatic proteins were found. Sialidase treatment of VWF resulted in a complete lack of Siglec-5 binding. In contrast, sialidase treatment left interactions between FVIII and Siglec-5 unaffected. FVIII and VWF also bound to cellsurface exposed Siglec-5, as was visualized by classical immunostaining as well as by Duolinkproximity ligation assays. Co-localization of FVIII and VWF with early endosomal markers further suggested that binding to Siglec-5 is followed by endocytosis of the proteins. Finally, overexpression of human Siglec-5 in murine hepatocytes following hydrodynamic gene transfer resulted in a significant decrease in plasma levels of FVIII and VWF in these mice. CONCLUSIONS: Our data indicate that FVIII and VWF may act as a ligand for Siglec-5, and that Siglec-5 may contribute to the regulation of plasma levels of the FVIII/VWF complex.
BACKGROUND:Factor VIII (FVIII) and von Willebrand factor (VWF) circulate in plasma in a tight non-covalent complex, being critical to hemostasis. Although structurally unrelated, both share the presence of sialylated glycan-structures, making them potential ligands for sialic-acid-binding-immunoglobulin-like-lectins (Siglecs). DESIGN AND METHODS: We explored the potential interaction between FVIII/VWF and Siglec-5, a receptor expressed in macrophages using various experimental approaches, including binding experiments with purified proteins and cell-binding studies with Siglec-5 expressing cells. Finally, Siglec-5 was overexpressed in mice via hydrodynamic gene transfer. RESULTS: In different systems using purified proteins, saturable, dose-dependent and reversible interactions between a soluble Siglec-5 fragment and both hemostatic proteins were found. Sialidase treatment of VWF resulted in a complete lack of Siglec-5 binding. In contrast, sialidase treatment left interactions between FVIII and Siglec-5 unaffected. FVIII and VWF also bound to cellsurface exposed Siglec-5, as was visualized by classical immunostaining as well as by Duolinkproximity ligation assays. Co-localization of FVIII and VWF with early endosomal markers further suggested that binding to Siglec-5 is followed by endocytosis of the proteins. Finally, overexpression of humanSiglec-5 in murine hepatocytes following hydrodynamic gene transfer resulted in a significant decrease in plasma levels of FVIII and VWF in these mice. CONCLUSIONS: Our data indicate that FVIII and VWF may act as a ligand for Siglec-5, and that Siglec-5 may contribute to the regulation of plasma levels of the FVIII/VWF complex.
Authors: Aaron F Carlin; Yung-Chi Chang; Thomas Areschoug; Gunnar Lindahl; Nancy Hurtado-Ziola; Charles C King; Ajit Varki; Victor Nizet Journal: J Exp Med Date: 2009-07-13 Impact factor: 14.307
Authors: Carina J van Schooten; Shirin Shahbazi; Evelyn Groot; Beatrijs D Oortwijn; H Marijke van den Berg; Cécile V Denis; Peter J Lenting Journal: Blood Date: 2008-06-16 Impact factor: 22.113
Authors: Nicoletta Sorvillo; Robin B Hartholt; Esther Bloem; Magdalena Sedek; Anja ten Brinke; Carmen van der Zwaan; Floris P van Alphen; Alexander B Meijer; Jan Voorberg Journal: Haematologica Date: 2015-12-03 Impact factor: 9.941
Authors: Laura L Swystun; Colleen Notley; Ilinca Georgescu; Jesse D Lai; Kate Nesbitt; Paula D James; David Lillicrap Journal: J Thromb Haemost Date: 2019-03-19 Impact factor: 5.824
Authors: Qianyi Ma; Ayse B Ozel; Shweta Ramdas; Beth McGee; Rami Khoriaty; David Siemieniak; Hong-Dong Li; Yuanfang Guan; Lawrence C Brody; James L Mills; Anne M Molloy; David Ginsburg; Jun Z Li; Karl C Desch Journal: Blood Date: 2014-09-10 Impact factor: 22.113
Authors: Laura L Swystun; Jesse D Lai; Colleen Notley; Ilinca Georgescu; A Simonne Paine; Jeff Mewburn; Kate Nesbitt; Kai Schledzewski; Cyrill Géraud; Julia Kzhyshkowska; Sergij Goerdt; Wilma Hopman; Robert R Montgomery; Paula D James; David Lillicrap Journal: J Clin Invest Date: 2018-08-20 Impact factor: 14.808
Authors: Natalia Rydz; Laura L Swystun; Colleen Notley; Andrew D Paterson; J Jacob Riches; Kate Sponagle; Boonchai Boonyawat; Robert R Montgomery; Paula D James; David Lillicrap Journal: Blood Date: 2013-03-25 Impact factor: 22.113